| Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 366 (9503), 2087-2106, 2005 | 6369 | 2005 |
| Polychemotherapy for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 352 (9132), 930-942, 1998 | 2176 | 1998 |
| Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J O’Shaughnessy, D Miles, S Vukelja, V Moiseyenko, JP Ayoub, ... Journal of clinical oncology 20 (12), 2812-2823, 2002 | 1476 | 2002 |
| Identification of molecular apocrine breast tumours by microarray analysis P Farmer, H Bonnefoi, V Becette, M Tubiana-Hulin, P Fumoleau, ... Breast Cancer Research 7, 1-1, 2005 | 986 | 2005 |
| Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior … J Baselga, KA Gelmon, S Verma, A Wardley, PF Conte, D Miles, G Bianchi, ... Journal of clinical oncology 28 (7), 1138-1144, 2010 | 858 | 2010 |
| Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial H Roché, P Fumoleau, M Spielmann, JL Canon, T Delozier, D Serin, ... Journal of Clinical Oncology 24 (36), 5664-5671, 2006 | 789 | 2006 |
| Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. R Bruno, D Hille, A Riva, N Vivier, WW ten Bokkel Huinnink, ... Journal of clinical oncology 16 (1), 187-196, 1998 | 494 | 1998 |
| 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, ... The lancet oncology 14 (8), 741-748, 2013 | 469 | 2013 |
| Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. JM Nabholtz, K Gelmon, M Bontenbal, M Spielmann, G Catimel, P Conte, ... Journal of Clinical Oncology 14 (6), 1858-1867, 1996 | 466 | 1996 |
| Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. P Fumoleau, FM Delgado, T Delozier, A Monnier, MA Gil Delgado, ... Journal of clinical oncology 11 (7), 1245-1252, 1993 | 432 | 1993 |
| Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer MM Borner, P Schöffski, R De Wit, F Caponigro, G Comella, A Sulkes, ... European Journal of Cancer 38 (3), 349-358, 2002 | 399 | 2002 |
| Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory … S Ladoire, L Arnould, L Apetoh, B Coudert, F Martin, B Chauffert, ... Clinical cancer research 14 (8), 2413-2420, 2008 | 397 | 2008 |
| Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer P Fumoleau, R Largillier, C Clippe, V Dieras, H Orfeuvre, T Lesimple, ... European Journal of Cancer 40 (4), 536-542, 2004 | 391 | 2004 |
| Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer MD Pegram, T Pienkowski, DW Northfelt, W Eiermann, R Patel, ... Journal of the National Cancer Institute 96 (10), 759-769, 2004 | 372 | 2004 |
| Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer E Thomas, J Tabernero, M Fornier, P Conté, P Fumoleau, A Lluch, ... Journal of Clinical Oncology 25 (23), 3399-3406, 2007 | 363 | 2007 |
| Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic … AC Wolff, AA Lazar, I Bondarenko, AM Garin, S Brincat, L Chow, Y Sun, ... Journal of clinical oncology 31 (2), 195-202, 2013 | 337 | 2013 |
| Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal … J Cortés, P Fumoleau, GV Bianchi, TM Petrella, K Gelmon, X Pivot, ... Journal of clinical oncology 30 (14), 1594-1600, 2012 | 318 | 2012 |
| Immunoscintigraphy of colon carcinoma. JF Chatal, JC Saccavini, P Fumoleau, JY Douillard, C Curtet, M Kremer, ... Journal of Nuclear Medicine: Official Publication, Society of Nuclear …, 1984 | 304 | 1984 |
| Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene … V Valero, J Forbes, MD Pegram, T Pienkowski, W Eiermann, ... Journal of clinical oncology 29 (2), 149-156, 2011 | 298 | 2011 |
| Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with … C Jacquillat, D Khayat, P Banzet, M Weil, P Fumoleau, MF Avril, M Namer, ... Cancer 66 (9), 1873-1878, 1990 | 296 | 1990 |
